Noveris Announces Life Offering

Executive Summary

• Noveris Health Sciences Inc. announced a non‑brokered private placement (“LIFE Offering”) of 6,250,000 to 10,416,666 units at $0.24 per unit, targeting gross proceeds between $1.5 M and $2.5 M.
• Each unit consists of one common share and one warrant to purchase an additional share at $0.30 exercisable for 24 months from closing.
• The offering is expected to close on or about April 24 2026 (or within 45 days of the release), subject to customary conditions and CSE approval.

Key Details

• Units Offered: Minimum 6,250,000; Maximum 10,416,666.
• Price per Unit: $0.24.
• Gross Proceeds Target: Minimum $1,500,000; Maximum $2,500,000.
• Unit Composition:
• 1 common share of Noveris Health Sciences Inc.
• 1 common share purchase warrant (exercise price $0.30, exercisable for 24 months from closing).
• Finder’s Fees: Up to 5% of gross proceeds may be paid to cash finders introducing investors.
• Geographic Availability: Offered in all Canadian provinces except Québec; Canadian resident subscribers not subject to a hold period under CSE rules (insiders/consultants subject to four‑month hold).
• Closing Timeline: Expected on or about April 24, 2026, or any date within 45 days of this release.
• Regulatory Conditions: Subject to compliance with NI 45‑106 and approval by the Canadian Securities Exchange (CSE).
• Offering Documentation: Available via the company’s profile at www.sedarplus.ca and on the company website.

Notable Quotes

• “We are pleased to announce the LIFE Offering, which will provide essential capital to advance our innovative mental‑health therapeutics pipeline.” – Jason Birmingham, Chief Executive Officer.